NECTIN4 and neoplasm: While we anticipate tumor cell killing to be a minor contributor to the decline observed on day 1, further mechanistic studies using Nectin-4–independent methods, such as histological assessment and flow cytometry, will be valuable to distinguish drug-target engagement from tumor cell viability effects.